Formosa Pharmaceuticals is a is a clinical stage biopharmaceutical company with primary focus in the areas of ophthalmology and oncology.

Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs.  Our proprietary APNT™ nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.

Development Pipeline

Scroll to Top